.png){kind=icon}
.png){kind=icon}
Return
Efficacy and Safety of Camrelizumab Combined with Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer: A Phase II Single-Arm Clinical Trial
.png){kind=icon}
PRE
AI
Y
L
X
H
X
DOI：10.1016/j.clon.2026.104293.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Quad-modality camrelizumab regimen shows high ORR/OS. • Grade ≥3 toxicities low; safe with definitive chemoradiation. • New immunoradiotherapy backbone for cervical cancer.
Journal
IF:
3
Papers:
4.7K
Citations:
4.7K
Organization
Cited Papers